CA3047136A1 - Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof - Google Patents

Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof Download PDF

Info

Publication number
CA3047136A1
CA3047136A1 CA3047136A CA3047136A CA3047136A1 CA 3047136 A1 CA3047136 A1 CA 3047136A1 CA 3047136 A CA3047136 A CA 3047136A CA 3047136 A CA3047136 A CA 3047136A CA 3047136 A1 CA3047136 A1 CA 3047136A1
Authority
CA
Canada
Prior art keywords
compound
mmol
group
amino
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3047136A
Other languages
English (en)
French (fr)
Inventor
Tinghu Zhang
Jianwei Che
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Isocure Biosciences Inc
Original Assignee
Isocure Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isocure Biosciences Inc filed Critical Isocure Biosciences Inc
Publication of CA3047136A1 publication Critical patent/CA3047136A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA3047136A 2016-12-19 2017-12-18 Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof Abandoned CA3047136A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662436328P 2016-12-19 2016-12-19
US62/436,328 2016-12-19
US201762536367P 2017-07-24 2017-07-24
US62/536,367 2017-07-24
PCT/US2017/067050 WO2018118793A1 (en) 2016-12-19 2017-12-18 Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof

Publications (1)

Publication Number Publication Date
CA3047136A1 true CA3047136A1 (en) 2018-06-28

Family

ID=62627122

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3047136A Abandoned CA3047136A1 (en) 2016-12-19 2017-12-18 Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof

Country Status (8)

Country Link
US (2) US11149032B2 (enExample)
EP (1) EP3555079A4 (enExample)
JP (1) JP2020502116A (enExample)
KR (1) KR20190092476A (enExample)
CN (1) CN110291085B (enExample)
AU (1) AU2017379796B2 (enExample)
CA (1) CA3047136A1 (enExample)
WO (1) WO2018118793A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6682043B2 (ja) * 2016-06-06 2020-04-15 イーライ リリー アンド カンパニー 変異体ｉｄｈ１阻害剤
WO2019213403A1 (en) 2018-05-02 2019-11-07 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
SG11202013175SA (en) * 2018-06-29 2021-01-28 Kinnate Biopharma Inc Inhibitors of cyclin-dependent kinases
CN111825666B (zh) * 2019-04-23 2024-03-08 上海仕谱生物科技有限公司 二聚或多聚体形式的突变型idh抑制剂
EP4210766A4 (en) * 2020-09-14 2024-11-06 Totus Medicines Inc. THERAPEUTIC CONJUGATES
CN120554346A (zh) * 2024-02-28 2025-08-29 中国科学院上海药物研究所 一类噁唑酮取代的嘧啶胺化合物及其制备方法、药物组合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030024659A (ko) * 2000-02-17 2003-03-26 암겐 인코포레이티드 키나제 억제제
AR064571A1 (es) * 2006-12-28 2009-04-08 Basf Ag Pirimidinas sustituidas en posicion 2 por heterociclos nitrogenados, medicamentos y composiciones farmaceuticas que las contienen y usos de las mismas en el tratamiento del cancer.
MX342326B (es) * 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
WO2016044781A1 (en) * 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
WO2017140758A1 (en) * 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
JP6682043B2 (ja) * 2016-06-06 2020-04-15 イーライ リリー アンド カンパニー 変異体ｉｄｈ１阻害剤

Also Published As

Publication number Publication date
CN110291085B (zh) 2023-01-24
AU2017379796B2 (en) 2021-10-21
WO2018118793A1 (en) 2018-06-28
EP3555079A1 (en) 2019-10-23
US20200071309A1 (en) 2020-03-05
JP2020502116A (ja) 2020-01-23
CN110291085A (zh) 2019-09-27
EP3555079A4 (en) 2020-08-19
KR20190092476A (ko) 2019-08-07
US20210403460A1 (en) 2021-12-30
AU2017379796A1 (en) 2019-07-04
US11149032B2 (en) 2021-10-19

Similar Documents

Publication Publication Date Title
US20210403460A1 (en) Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof
IL293962B2 (en) Mutant KRAS protein inhibitors
CN113286794A (zh) Kras突变蛋白抑制剂
CN106661034A (zh) 作为tlr7激动剂的吡咯并嘧啶化合物
EP3675860B1 (en) Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof
BR112021011147A2 (pt) Benzamidas de derivados de pirazolil-amino-pirimidinila e composições e métodos das mesmas
CZ20023945A3 (cs) Substituované pyrrolopyridinové deriváty pro použití jako inhibitory fosfodiesterázy
JP2022521537A (ja) イミダゾピリジニル化合物及び増殖性障害の処置のためのその使用
KR102920599B1 (ko) 항종양 활성을 갖는 화합물 및 이의 용도
WO2020215998A1 (zh) 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
CA3222626A1 (en) Compound having anti-tumor activity and use thereof
CN116888107B (zh) 作为Wee-1抑制剂的稠环化合物
US20210101899A1 (en) Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof
CN115073469B (zh) 吡咯并嘧啶类化合物作为激酶抑制剂的制备及其应用
CA3206871A1 (en) Pyrimidine compound as wee-1 inhibitor
CN111278827B (zh) 突变型异柠檬酸脱氢酶抑制剂、组合物及其方法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20240402